Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+0.70002.83%
Pre-market: 26.941.49+5.85%04:59 EDT
Volume:296.73K
Turnover:7.49M
Market Cap:699.90M
PE:-9.47
High:25.77
Open:25.17
Low:24.78
Close:24.75
Loading ...

William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform

MT Newswires Live
·
10 Mar

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

TIPRANKS
·
10 Mar

Prelude Therapeutics sees cash runway into 2Q26

TIPRANKS
·
10 Mar

Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James

TIPRANKS
·
10 Mar

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

GlobeNewswire
·
10 Mar

Press Release: Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Dow Jones
·
10 Mar

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

GlobeNewswire
·
10 Mar

Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4

MT Newswires Live
·
10 Mar

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

Benzinga
·
10 Mar

Trevi Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
10 Mar

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
10 Mar

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
10 Mar

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

GlobeNewswire
·
10 Mar

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

Dow Jones
·
10 Mar

Beam Therapeutics Announces Pricing of Underwritten Offering

GlobeNewswire
·
10 Mar

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire
·
10 Mar